| Code | CSB-RA004936MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to BI-655064, targeting CD40, a critical costimulatory receptor belonging to the tumor necrosis factor receptor superfamily. CD40 is expressed on antigen-presenting cells, B lymphocytes, and various non-immune cells, playing a pivotal role in adaptive immune responses through its interaction with CD40 ligand (CD154). This interaction triggers essential signaling cascades that regulate B cell activation, antibody class switching, germinal center formation, and T cell priming. Dysregulated CD40 signaling is implicated in numerous pathological conditions, including autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, as well as inflammatory disorders and certain malignancies.
BI-655064 is a fully humanized IgG1 monoclonal antibody designed to block CD40-CD154 interactions without depleting CD40-expressing cells, distinguishing it from earlier CD40-targeting therapeutics. This biosimilar antibody serves as a valuable research tool for investigating CD40-mediated immune mechanisms, exploring therapeutic interventions in autoimmune and inflammatory disease models, and studying B cell biology and immune regulation.
There are currently no reviews for this product.